

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
2 October 2003 (02.10.2003)

PCT

(10) International Publication Number  
**WO 03/080071 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/661**

(21) International Application Number: **PCT/KR03/00593**

(22) International Filing Date: 25 March 2003 (25.03.2003)

(25) Filing Language: Korean

(26) Publication Language: English

(30) Priority Data:

10-2002-0016029 25 March 2002 (25.03.2002) KR

10-2002-0049766 22 August 2002 (22.08.2002) KR

10-2002-0064308 21 October 2002 (21.10.2002) KR

(71) Applicant (for all designated States except US): **BIOSYN-ERGEN, INC.** [KR/KR]; 4F. College of Medicine BLDG, Hallym University, 1 Okchon-Dong, Chuncheon, Kangwon-Do 200-702 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KIM, Yung-Hi** [KR/KR]; 201-607 Hyundai Apt., 427 Hupyeong-dong, Chuncheon, Kangwon-do 200-959 (KR). **SONG,**

**Dong-Keun** [KR/KR]; 101-403 Dong-Ah Apt, 893 Hupyeong-dong, Chuncheon, Kangwon-do 200-963 (KR). **SUH, Hong-Won** [KR/KR]; 101-204 Dong-Ah Apt, 893 Hupyeong-dong, Chuncheon, Kangwon-do 200-963 (KR). **HUH, Sung-Oh** [KR/KR]; 108-101 Suksa Dawoo Apt, 724 Suksa-dong, Chuncheon, Kangwon-do 200-936 (KR).


(74) Agent: **KIM, Seog-Hyun**; 9th Floor, Daekyung Building, 120, 2-ka Taepyung-ro, Chung-ku, Seoul 100-724 (KR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]


(54) Title: NOVEL THERAPEUTICAL USE OF AGONIST LIGANDS SPECIFIC TO G2A RECEPTOR



A



B



C

(57) Abstract: The present invention relates to novel therapeutical use of agonist ligands specific to G2A receptor. More particularly, the present invention relates to methods for treating a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, or with microbial infection, in a subject, comprising administering LPC (lysophosphatidylcholine), SPC(sphingophosphorylcholine) or derivatives thereof to the subject. The agonist ligands for G2A receptor according to the present invention and pharmaceutical- or therapeutical composition comprising said ligands can be used effectively in treatment of a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, specifically inflammatory diseases and diseases associated with ischemia-reperfusion injury as well as microbial infection.